News EMA panel endorses AI for MASH clinical trials PathAI's artificial intelligence tool for diagnosing MASH has become the first to be recommended under the EMA's Qualification Opinion framework.
News J&J's nipocalimab fast-tracked for Sjogren's disease Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.
News FDA chooses flu vaccine strains despite cancelled meeting The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season – without the input of its external advisors.
News FDA starts review of Roche's Gazyva in lupus nephritis FDA starts a review of Roche's Gazyva as a treatment for lupus nephritis, an indication that analysts think could unlock renewed sales growth.
News Lawrence Tallon will lead MHRA after June Raine retires Lawrence Tallon has been named head of the MHRA, effective 1st April, replacing Dame June Raine who is retiring.
News Australia stands firm on 'no' to Alzheimer's drug Leqembi Eisai and Biogen have been unable to persuade Australia's medicines regulator to approve their Alzheimer's therapy Leqembi with a narrower label.
News MIT team develops 'years-long' drug delivery tech Researchers in the US have devised a new depot system that could provide months or even years of delivery from a single subcutaneous injection.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl